Goldman Downgrades Gilead Sciences: 'We Find It Difficult To See The Stock's Multiple Expanding'Benzinga • 05/28/19
Lawsuit accuses Gilead of propping up cost of HIV treatments by blocking generic competitionCNBC • 05/14/19
Is Gilead Stock Seeing The Light Of O'Day? HIV Drugs Bolster ViewsInvestors Business Daily • 05/03/19